Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report) yesterday and set a price target of $12.00.
Sumant Kulkarni has given his Buy rating due to a combination of factors related to Voyager Therapeutics’ strategic positioning and future prospects. The company is expected to benefit from several upcoming catalysts in 2025 and 2026, with a financial runway extending into mid-2027, which supports the potential for significant growth. The maintenance of timelines for key programs, particularly in the area of anti-tau therapies for Alzheimer’s disease, is a positive indicator of pipeline progress.
Additionally, despite the removal of the VY9323 program from the model, the adjusted price target remains at $12, reflecting confidence in other ongoing initiatives. The partnership with NBIX for the GBA1 Parkinson’s disease program and potential milestones from collaborations with Alexion and Novartis further bolster the company’s outlook. External validations of Voyager’s TRACER capsid technology also contribute to the overall positive assessment, reinforcing the Buy recommendation.
In another report released today, Citi also reiterated a Buy rating on the stock with a $11.00 price target.
VYGR’s price has also changed moderately for the past six months – from $6.220 to $4.060, which is a -34.73% drop .